Javier Morales, MD, FACP, FACE

Articles

Teplizumab for Delaying Onset and Progression of T1D

December 10, 2024

Panelists discuss how teplizumab, an anti-CD3 monoclonal antibody, delays the onset and progression of type 1 diabetes by modulating immune response and preserving ß-cell function in high-risk individuals.

Who Should We Screen for T1D?

December 10, 2024

Panelists discuss screening for T1D for individuals at higher risk, such as those with a family history of T1D, autoimmune conditions, or certain genetic markers, to identify early signs of the disease and enable timely intervention.

Antibody Screening Tests for T1D

December 10, 2024

Panelists discuss how antibody screening tests for type 1 diabetes (T1D), including tests for insulin autoantibodies (IAA), glutamic acid decarboxylase (GAD) antibodies, and other markers can help identify individuals at risk for developing the disease before clinical symptoms appear, enabling earlier monitoring and potential intervention.

Consequences of Delaying Intervention in Stage 2 T1D

December 10, 2024

Panelists discuss how delaying intervention in stage 2 type 1 diabetes, when dysglycemia is present but clinical symptoms have not yet developed, can lead to further ß-cell deterioration and worsen long-term glycemic control, ultimately increasing the risk of complications.

Examining the Stages of T1D Progression

December 10, 2024

Panelists discuss how the progression of type 1 diabetes unfolds through distinct stages, from the preclinical phase of autoimmunity to the onset of clinical diabetes, emphasizing the importance of early detection and intervention to improve patient outcomes.

Guidelines on Screening for T1D

December 10, 2024

Panelists discuss how adhering to screening guidelines for type 1 diabetes enables early detection and intervention, improving patient outcomes and delaying disease progression through timely treatments like teplizumab.

Assessing the Burden of T1D

December 10, 2024

Panelists discuss how managing the clinical, financial, and quality-of-life burdens of type 1 diabetes (T1D) requires early intervention, proactive care strategies, and the use of treatments like teplizumab to improve patient outcomes and reduce long-term complications.

Teplizumab Therapy to Delay Onset and Progression of T1D

December 05, 2024

Panelists discuss how teplizumab therapy can delay the onset and progression of type 1 diabetes (T1D) by preserving β-cell function and reducing the risk of developing full-blown diabetes in at-risk individuals.

Teplizumab Use in Practice

December 05, 2024

Panelists discuss clinical use of teplizumab including patient selection, navigating approval processes, and managing the 14-day infusion regimen to optimize outcomes and delay the progression of type 1 diabetes.